Introduction Suzhou Transcenta Therapeutics Co., Ltd. is a biotechnology company that specializes in discovering and developing innovative antibody-based therapies for cancer and fibrotic diseases. The company was established in 2013 by experienced professionals in the industry and is situated in Biobay Suzhou, a rapidly growing biotech incubator in China. Transcenta utilizes its exclusive immune tolerance breaking technology (IMBT) to generate diverse epitope lead antibodies. The company has formed numerous partnerships for antibody discovery and co-development based on this technology. Additionally, Transcenta has developed a panel of second-generation immuno-oncology antibodies targeting different components of the tumor microenvironment, allowing for the testing of combination therapeutic interventions with its PD-L1 antibody. |
Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 8 |
Bispecific antibody | 3 |
Radionuclide Drug Conjugates (RDC) | 1 |
Fusion protein | 1 |
Antibody drug conjugate (ADC) | 1 |
Target |
Mechanism CLDN18.2 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PDL1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GREM1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 May 2025 |
Sponsor / Collaborator |
Start Date31 Oct 2023 |
Sponsor / Collaborator |
Start Date14 Aug 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Osemitamab ( CLDN18.2 ) | CLDN18.2 positive Gastroesophageal junction adenocarcinoma More | Phase 3 |
TST 003 ( GREM1 ) | Adenocarcinoma of large intestine More | Phase 2 Clinical |
MSB-2311 ( PDL1 ) | Solid tumor More | Phase 2 |
TST-005 ( PDL1 x TGF-β ) | Vulvar Neoplasms More | Phase 1 |
TST-006 ( CLDN18.2 x PDL1 ) | Neoplasms More | Preclinical |